STROKE-CARD REGISTRY: Extension of Standard Care in Patients With Ischemic Stroke and Transient Ischemic Attack

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Stroke is the second leading cause of death and one of the main contributors to disability. Patients who survive the acute phase of ischemic stroke and those with transient ischemic attack (TIA) are at high risk of subsequent vascular events. Importantly, recurrent strokes are associated with a higher social and economic impact, higher case fatality, and worse clinical outcome than first-ever strokes. The burden of post-stroke complications, residual deficits, and inadequate medical and psychosocial care all contribute to long-term disability and reduced quality of life in these patients. The Department of Neurology of the Medical University Innsbruck undertook the STROKE-CARD trial (NCT02156778) between 2014 and 2018 with follow-up until 2019 to evaluate the efficacy of the Post-Stroke disease-management program STROKE-CARD care. After implementation of STROKE-CARD care, the investigators aim to document the quality of post-stroke care and compare outcome parameters to historical cohorts and the change over time. Furthermore the investigators aim to gain a large data-resource for future research of biomarkers, disease mechanisms, prognosis and imaging mechanisms for R\&D.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with acute ischemic stroke or high-risk TIA (ABCD2-Score ≥ 4 points) treated at the Department of Neurology of each study center within 30 days after onset

• Age ≥ 18 years

• Written informed consent

Locations
Other Locations
Austria
Medical University Innsbruck
RECRUITING
Innsbruck
Hospital St. John of God
RECRUITING
Vienna
Contact Information
Primary
Christian Böhme, MD
christian.boehme@i-med.ac.at
+43 512 504
Backup
Ulrike Pachmann, MSc
ulrike.pachmann@vascage.at
+43 512 554435
Time Frame
Start Date: 2020-12-09
Estimated Completion Date: 2027-07-31
Participants
Target number of participants: 5000
Related Therapeutic Areas
Sponsors
Collaborators: Medical University Innsbruck, St John of God Hospital, Vienna
Leads: VASCage GmbH

This content was sourced from clinicaltrials.gov